Cara Therapeutics enters into commercial license agreement with Enteris BioPharma
Cara Therapeutics announced a non-exclusive commercial license agreement with Enteris BioPharma for oral formulation rights to Enteris’ Peptelligence® Technology. Enteris will receive an upfront payment of $8 million, including $4 million in cash and $4 million in Cara common stock. August 21, 2019